Skip to main content
Premium Trial:

Request an Annual Quote

Celera and Elitra Pharma Sequence Aspergillus Fumigatus

NEW YORK, May 7 – Elitra Pharmaceuticals on Monday announced the complete sequencing to a 10X depth of coverage of the Aspergillus fumigatus genome. The sequencing work was performed by Celera Genomics under exclusive agreement.

“Sequencing the entire Aspergillus genome is a major technical achievement, and will accelerate our efforts to characterize and file patents on essential gene drug targets in this organism,” J. Gordon Foulkes, Elitra executive vice president of research, said in a statement. “Celera's technical efficiency and professionalism in completing this sequencing project has been truly outstanding.”

A. fumigatus has approximately one third the number of genes present in humans, according to the company. The common fungus can cause life-threatening infection called aspergillus in people with compromised immune systems.

San Diego-based Elitra identifies, develops, and sells antimicrobial compounds targeted to gene products of pathogenic organisms. 

The Sanger Center is also engaged in sequencing A. fumigatus

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.